Today, we delve into three stocks currently trading below their intrinsic value, as assessed by fundamental analysis. These companies offer significant upside potential but also carry higher risk.
It’s crucial to emphasize that these are speculative investments suitable only for aggressive investors with a high-risk tolerance.
This analysis aims to shed light on potential opportunities, not provide investment advice about stocks that Wall Street analysts expect to rise by more than 35% if all goes well.
So without further delay, Let’s explore these high-risk, high-reward stocks in detail.
1. Intellia Therapeutics
Intellia Therapeutics (NASDAQ:) is a small-cap biotech company with the main objective being to create treatments for genetic diseases.
It generated $28.9 million in revenue in the first quarter from collaborations and licensing agreements.
It will report its next results on October 31 and is expected to report a 61.1% increase in revenue by 2024.
Source: InvestingPro
It plans to initiate a trial later this year to test NTLA 2001 for the treatment of amyloidosis and has a collaboration with Regeneron (NASDAQ:) to develop and commercialize NTLA-2001 once it is approved.
Intellia Therapeutics’ future as a biotechnology company depends on obtaining regulatory approval for its clinical candidates. Once approved, these therapies have the potential to address important medical needs while capturing substantial market share.
The commercial success of its lead candidates (if and when they are approved) will have a significant impact on the company’s financials.
Investors should understand the risks associated with clinical-stage biotech stocks, which include clinical trial failure, regulatory risks and other market uncertainties.
In addition, developing a successful therapy takes time. As a result, Intellia represents a high-risk, potentially high-reward investment opportunity.
The market is very bullish; of the 26 ratings, 20 are buy, six are hold and none are sell.
The market sees potential at $69.84% based on the price of $21.46 at the close of the week.
Source:…
..